Current location:entertainment >>
WHO endorses China's Sinopharm COVID
entertainment42512People have gathered around
IntroductionWorkers prepare to unload the COVID-19 vaccines from China at the Baghdad International Airport in B ...
Workers prepare to unload the COVID-19 vaccines from China at the Baghdad International Airport in Baghdad, Iraq, April 11, 2021. [Photo/Xinhua]
The World Health Organization (WHO) validated on Friday the COVID-19 vaccine developed by China's Sinopharm for emergency use, a move set to boost global vaccine rollout, particularly in the developing world.
"This afternoon, the WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," said WHO Director General Dr. Tedros Adhanom Ghebreyesus at a press briefing.
"This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine," he said.
COVAX is a global coalition that works to ensure fair and equitable access to COVID-19 vaccines around the world.
In addition to the Sinopharm's BBIBP-CorV vaccine, the WHO had previously listed the COVID-19 vaccine developed by Pfizer/BioNTech, two versions of the AstraZeneca/Oxford vaccine, the Janssen vaccine and the Moderna vaccine for emergency use.
In an official press release, WHO Assistant Director General for Access to Health Products Dr. Mariangela Simao said that the addition of the Sinopharm vaccine has "the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk."
First COVID-19 jab with vial monitor
The jab produced by the Beijing Bio-Institute of Biological Products Co. Ltd., a subsidiary of the China National Biotec Group, is an inactivated vaccine with easy storage requirements, which makes it highly suitable for use in low-resource settings.
It is also the first vaccine that will carry a vial monitor, a small sticker on the vials that changes color if the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.
According to the WHO's Strategic Advisory Group of Experts on Immunization (SAGE), the Sinopharm vaccine is recommended for use in adults 18 years and older in a two-dose schedule with a spacing of three to four weeks.
Though few adults over 60 years were enrolled in clinical trials and efficacy could not be estimated in this age group, the WHO is not recommending an upper age limit for the Sinopharm vaccine, because reviewed data have suggested that the vaccine is likely to have a protective effect in older persons, according to the WHO press release.
"There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations," said the WHO press release, which recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring.
Assessment by SAGE has shown that the Sinopharm vaccine had been authorized by 45 countries or jurisdictions for use in adults 18 years or older, where more than 65 million doses had been administered through emergency use programs. No safety concerns have been identified from pre-clinical or repro/tox (reproductive toxicity) studies, while most adverse events were mild to moderate, such as injection pain, headache and fatigue.
Global public good
As of Wednesday, more than 1.1 billion COVID-19 vaccine doses had been administered globally, but over 80 percent of those had been administered in high and upper-middle income countries, while just 0.3 percent in low-income countries, according to Tedros.
With the WHO's validation for emergency use, the Sinopharm vaccine, as the first COVID-19 vaccine developed by a non-western country, is expected to accelerate vaccine rollout in many low and middle-income countries through purchase and delivery by the WHO-led COVAX initiative.
According to Yu Qingming, chairman of the Sinopharm Group, this year's output of the Sinopharm vaccine is targeted at more than one billion doses, and is expected to reach three billion doses in the future.
China has decided to provide ten million COVID-19 vaccine doses to the COVAX initiative to meet the urgent needs of developing countries, a concrete step to deliver on the promise to make vaccines a global public good.
This is also an important achievement in the field of epidemic prevention and control. China was the first to have put the pandemic under control, and successfully developed one of the earliest vaccines in the world.
Adhering to the concept of a community with a shared future for health, China has so far provided vaccine assistance selflessly to more than 80 countries and three international organizations, exported vaccines to more than 40 countries, and collaborated with over ten countries in vaccine research and development (R&D) and production.
The validation of the Chinese vaccine, which is the result of high technology content and high R&D investment, has also strengthened the international recognition of the "Made in China" and "R&D in China labels."
Tags:
Reprint:Friends are welcome to share on the Internet, but please indicate the source of the article when reprinting it.“Stellar Series news portal”。http://luxembourg.unhasdecoradas.org/content-24b099901.html
Related articles
Red Lobster seeks bankruptcy protection after closing some restaurants
entertainmentRed Lobster, the casual dining chain that brought seafood to the masses with inventions like popcorn ...
Read moreEconomic Watch: China remains popular destination for foreign investment
entertainmentAerial photo taken on Dec. 28, 2021 shows the new Tiexi Plant of BMW Brilliance Automotive (BBA) und ...
Read moreMore efforts called on to energize consumption
entertainmentA pedestrian walks past the People's Bank of China, the country's central bank, in Beijing on May 22 ...
Read more
Popular articles
- Student fatally shot, suspect detained at Georgia's Kennesaw State University
- China, Norway share common goals at ministerial meeting
- Xi extends condolences over death of Namibia's Geingob
- Xictionary: High
- Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky
- Bridge on Xiong'an Expressway in place
Latest articles
Who is Jacob Zuma, the former South African president disqualified from next week's election?
Councilors vow to explain Article 23 to HK residents
Embassy welcomes 'home' overseas Chinese
Xi extends condolences over death of Namibia's Geingob
Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky
Xi congratulates Nangolo Mbumba on assuming Namibia's presidency
LINKS
- China's interbank treasury bond index opens higher Monday
- Jodie Turner
- Alves granted €1m bail after sexual assault conviction
- Son on target as South Korea beat Thailand 3
- Alves granted €1m bail after sexual assault conviction
- Hotpot festival spices up Chongqing's consumer market
- China secures last four spots in Thomas & Uber Cup
- China's interbank treasury bond index opens higher Monday
- Olympic champion Ye qualifies for Paris 2024
- Brazil draw six